Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Melanoma: Optimizing Selection of Adjuvant Therapy

July 18th 2019

Adjuvant Therapy Options in Melanoma Treatment

July 18th 2019

Neoadjuvant Therapy in the Treatment of Melanoma

July 18th 2019

Melanoma: BRAF Status and a Neoadjuvant Therapy Approach

July 18th 2019

Long Shares Insight on Pivotal Data in BRAF-Mutant Melanoma

July 10th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the activity of the combination of dabrafenib and trametinib alone as well as in combination with spartalizumab in patients with advanced BRAF V600E-mutant melanoma.

FDA Approval Sought for Extended Pembrolizumab Dosing Schedule for Select Indications

July 9th 2019

The FDA has accepted 6 supplemental biologics license applications for review to update the dosing schedule for pembrolizumab (Keytruda) to include an every-6-weeks option at 400 mg over 30-minute infusions.

Dr. Khushalani on Reasoning for the CA045-001 Trial

July 9th 2019

Nikhil Khushalani, MD, discusses the CA045-001 study, a phase III, randomized study that compared bempegaldesleukin plus nivolumab versus nivolumab monotherapy in patients with previously untreated, unresectable, or metastatic melanoma.

Dr. Sullivan on Practice-Changing COMBI-d and COMBI-v Trials

July 5th 2019

Ryan J. Sullivan, MD, discusses the results of the COMBI-d and COMBI-v studies that led to changes in practice for patients with BRAF V600-mutant unresectable or metastatic melanoma.

Dr. Polsky on Using ctDNA as a Biomarker for Melanoma

July 2nd 2019

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.

Cemiplimab Approved in Europe for Cutaneous Squamous Cell Carcinoma

July 1st 2019

The European Commission approved cemiplimab (Libtayo) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

Adding PD-1 Inhibitor to Dabrafenib/Trametinib May Improve Outcomes in BRAF+ Melanoma

June 28th 2019

Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.

Unmet Needs and Future Treatments of Metastatic Melanoma

June 28th 2019

The Use of Dual Targeted Therapy in Metastatic Melanoma

June 28th 2019

Management of Patients with BRAF-Mutated Melanoma

June 28th 2019

Combination Therapy in Mutated Melanoma

June 28th 2019

The Role of BRAF Mutations in Melanoma

June 28th 2019

Future of Treating Melanoma

June 28th 2019

Novel Agents for the Treatment of Melanoma

June 28th 2019

Melanoma: Progression After Immunotherapy

June 28th 2019

Intralesional Therapy for Metastatic Melanoma

June 28th 2019